PreserVision, Biotrue Brands Help Bausch US Consumer Health See Turnaround More Clearly
Executive Summary
Bausch + Lomb’s PreserVision supplement sales grew 17% in Q3, driving 11% growth its US consumer health business. CEO Joseph Papa says Bausch is “making great progress and expect the internal organization design” of its planned spin-off of Bausch + Lomb to be completed in a year.
You may also be interested in...
US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.
Bausch Shines Planned Spin-Out, Launches First US Preservative-Free OTC Antihistamine Eye Drops
Bausch + Lomb’s Alaway Preservative-Free antihistamine eye drops launch in US, The Bausch Health Companies division planned as spin-out also recently gained South Korean approval for its Lumify OTC redness reliever drops and has submissions under review in other countries.
Consumer Health Brands On Nielsen ‘Breakthrough’ Leaders List Include Lumify As ‘Superstar’
“We selected Lumify based on its strong business performance in years one and two, and the success it had in growing a category through premiumization," says Nielsen’s BASES leader, Ben Macedo.